Format

Send to

Choose Destination
Clin Transl Sci. 2010 Jun;3(3):116-22. doi: 10.1111/j.1752-8062.2010.00186.x.

Vaccines as monotherapy and in combination therapy for prostate cancer.

Author information

1
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

Prostate cancer is the second leading cause of cancer death among men in the United States. Standard-of-care chemotherapy for metastatic castration-resistant prostate cancer is associated with significant but modest survival benefit, indicating a need for alternative and/or additional approaches. The use of therapeutic cancer vaccines for the treatment of prostate cancer represents a novel targeted therapeutic approach. Whereas vaccine strategies are being developed for the treatment of various stages of prostate cancer, this article focuses on novel vaccine strategies for castration-resistant prostate cancer that have been translated into late-stage clinical studies.

PMID:
20590682
PMCID:
PMC2914613
DOI:
10.1111/j.1752-8062.2010.00186.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center